Investigators have long been interested in the natural phenomenon of fetal and placental
cell trafficking into the maternal circulation. The scarcity of these circulating cells makes their …

The introduction of new technologies has dramatically changed the current practice of
prenatal screening and testing for genetic abnormalities in the fetus. Expanded carrier …

During the first trimester of pregnancy, extravillous trophoblasts (EVTs) invade into the
decidual interstitium to the first third of the myometrium, thereby anchoring the placenta to …

Placenta accreta spectrum (PAS) is a high-risk obstetrical condition associated with
significant morbidity and mortality. Current clinical screening modalities for PAS are not …

Objective Non‐invasive prenatal testing (NIPT) based on fetal cells in maternal blood has
the advantage over NIPT based on circulating cell‐free fetal DNA in that there is no …

The potential to use fetal cells in the mother's circulation during the first or second trimester
for prenatal diagnosis was described in 1968, but it has not been possible do develop a …

Blood contains a diverse cell population of low concentration hematopoietic as well as non-
hematopoietic cells. The majority of such rare cells may be bone marrow-derived progenitor …

Objective Trophoblastic fetal cells harvested from maternal blood have the capacity to be
used for copy number analyses in a cell‐based non‐invasive prenatal test (cbNIPT) …

Objectives Cystic fibrosis (CF) is one of the most common severe autosomal recessive
disorders. Prenatal or preconception CF screening is offered in some countries. A maternal …

New technologies analyzing fetal DNA in maternal blood have led to the wide commercial
availability of non-invasive prenatal testing (NIPT). We present here for clinicians the ethical …